Role of Immunotherapy in In Vitro Fertilization

Publication Date: August 1, 2018
Last Updated: March 14, 2022

Recommendatons

Given the lack of evidence to support improved IVF outcomes, there is good evidence to recommend against the routine use of low-dose aspirin to improve the outcome of live birth in ART cycles in the general population. (A)
331071

There is good evidence to recommend against the routine use of corticosteroids during stimulation to improve the outcome of live birth in ART cycles in the general population. (A)
331071

There is good evidence to recommend against the routine use of corticosteroids during the implantation window to improve the outcome of live birth in ART cycles in the general population. (A)
331071

There is insufficient evidence to recommend for or against local G-CSF to improve endometrial thickness in women with thin endometrium or clinical pregnancy rates with IVF. (C)
331071

There is insufficient evidence to recommend for or against G-CSF or GM-CSF administered locally or systemically to improve IVF outcomes. (C)
331071

There is insufficient evidence to routinely recommend intravenous fat emulsions for infertile women pursuing IVF. (C)
331071

There is insufficient evidence to recommend IVIG administration as part of IVF to improve IVF outcomes. (C)
331071

There is insufficient evidence to recommend adalimumab treatment to improve IVF outcome. (C)
331071

There is insufficient evidence to recommend intrauterine infusion of autologous peripheral mononuclear cells prior to ET to improve IVF outcome. (C)
331071

There is fair evidence that seminal plasma insemination as part of IVF improves clinical pregnancy rate. (B)
331071

However, there is fair evidence that it does not improve ongoing pregnancy or live-birth rates.
(B)
331071

There is insufficient evidence to support the recommendation either for or against antibody-free preparation of spermatozoa in improving IVF outcomes. (C)
This procedure has been rendered obsolete by the use of ICSI.
331071

There is insufficient evidence to recommend tacrolimus to improve IVF-ET outcome. (C)
331071

Recommendation Grading

Overview

Title

Role of Immunotherapy in In Vitro Fertilization

Authoring Organization

Publication Month/Year

August 1, 2018

Last Updated Month/Year

January 23, 2024

Supplemental Implementation Tools

Document Type

Guideline

External Publication Status

Published

Country of Publication

US

Document Objectives

The purpose of this guideline is to evaluate the role of immunomodulating therapy in ART

Target Patient Population

Patients with infertility

Inclusion Criteria

Female, Male, Adult

Health Care Settings

Ambulatory, Laboratory services, Outpatient

Intended Users

Nurse, nurse practitioner, physician, physician assistant

Scope

Management

Diseases/Conditions (MeSH)

D007246 - Infertility, D007167 - Immunotherapy, D007136 - Immunoglobulins, D016179 - Granulocyte Colony-Stimulating Factor, D000068879 - Adalimumab

Keywords

immunotherapy, adalimumab, infertility, ivig

Source Citation

Fertility and Sterility® Vol. 110, No. 3, August 2018 0015-0282